Food additive emulsifiers and cancer risk: Results from the French prospective NutriNet-Santé cohort.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
17
02
2023
accepted:
20
12
2023
medline:
15
2
2024
pubmed:
13
2
2024
entrez:
13
2
2024
Statut:
epublish
Résumé
Emulsifiers are widely used food additives in industrially processed foods to improve texture and enhance shelf-life. Experimental research suggests deleterious effects of emulsifiers on the intestinal microbiota and the metabolome, leading to chronic inflammation and increasing susceptibility to carcinogenesis. However, human epidemiological evidence investigating their association with cancer is nonexistent. This study aimed to assess associations between food additive emulsifiers and cancer risk in a large population-based prospective cohort. This study included 92,000 adults of the French NutriNet-Santé cohort without prevalent cancer at enrolment (44.5 y [SD: 14.5], 78.8% female, 2009 to 2021). They were followed for an average of 6.7 years [SD: 2.2]. Food additive emulsifier intakes were estimated for participants who provided at least 3 repeated 24-h dietary records linked to comprehensive, brand-specific food composition databases on food additives. Multivariable Cox regressions were conducted to estimate associations between emulsifiers and cancer incidence. Overall, 2,604 incident cancer cases were diagnosed during follow-up (including 750 breast, 322 prostate, and 207 colorectal cancers). Higher intakes of mono- and diglycerides of fatty acids (FAs) (E471) were associated with higher risks of overall cancer (HR high vs. low category = 1.15; 95% CI [1.04, 1.27], p-trend = 0.01), breast cancer (HR = 1.24; 95% CI [1.03, 1.51], p-trend = 0.04), and prostate cancer (HR = 1.46; 95% CI [1.09, 1.97], p-trend = 0.02). In addition, associations with breast cancer risk were observed for higher intakes of total carrageenans (E407 and E407a) (HR = 1.32; 95% CI [1.09, 1.60], p-trend = 0.009) and carrageenan (E407) (HR = 1.28; 95% CI [1.06, 1.56], p-trend = 0.01). No association was detected between any of the emulsifiers and colorectal cancer risk. Several associations with other emulsifiers were observed but were not robust throughout sensitivity analyses. Main limitations include possible exposure measurement errors in emulsifiers intake and potential residual confounding linked to the observational design. In this large prospective cohort, we observed associations between higher intakes of carrageenans and mono- and diglycerides of fatty acids with overall, breast and prostate cancer risk. These results need replication in other populations. They provide new epidemiological evidence on the role of emulsifiers in cancer risk. ClinicalTrials.gov NCT03335644.
Sections du résumé
BACKGROUND
BACKGROUND
Emulsifiers are widely used food additives in industrially processed foods to improve texture and enhance shelf-life. Experimental research suggests deleterious effects of emulsifiers on the intestinal microbiota and the metabolome, leading to chronic inflammation and increasing susceptibility to carcinogenesis. However, human epidemiological evidence investigating their association with cancer is nonexistent. This study aimed to assess associations between food additive emulsifiers and cancer risk in a large population-based prospective cohort.
METHODS AND FINDINGS
RESULTS
This study included 92,000 adults of the French NutriNet-Santé cohort without prevalent cancer at enrolment (44.5 y [SD: 14.5], 78.8% female, 2009 to 2021). They were followed for an average of 6.7 years [SD: 2.2]. Food additive emulsifier intakes were estimated for participants who provided at least 3 repeated 24-h dietary records linked to comprehensive, brand-specific food composition databases on food additives. Multivariable Cox regressions were conducted to estimate associations between emulsifiers and cancer incidence. Overall, 2,604 incident cancer cases were diagnosed during follow-up (including 750 breast, 322 prostate, and 207 colorectal cancers). Higher intakes of mono- and diglycerides of fatty acids (FAs) (E471) were associated with higher risks of overall cancer (HR high vs. low category = 1.15; 95% CI [1.04, 1.27], p-trend = 0.01), breast cancer (HR = 1.24; 95% CI [1.03, 1.51], p-trend = 0.04), and prostate cancer (HR = 1.46; 95% CI [1.09, 1.97], p-trend = 0.02). In addition, associations with breast cancer risk were observed for higher intakes of total carrageenans (E407 and E407a) (HR = 1.32; 95% CI [1.09, 1.60], p-trend = 0.009) and carrageenan (E407) (HR = 1.28; 95% CI [1.06, 1.56], p-trend = 0.01). No association was detected between any of the emulsifiers and colorectal cancer risk. Several associations with other emulsifiers were observed but were not robust throughout sensitivity analyses. Main limitations include possible exposure measurement errors in emulsifiers intake and potential residual confounding linked to the observational design.
CONCLUSIONS
CONCLUSIONS
In this large prospective cohort, we observed associations between higher intakes of carrageenans and mono- and diglycerides of fatty acids with overall, breast and prostate cancer risk. These results need replication in other populations. They provide new epidemiological evidence on the role of emulsifiers in cancer risk.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT03335644.
Identifiants
pubmed: 38349899
doi: 10.1371/journal.pmed.1004338
pii: PMEDICINE-D-23-00431
pmc: PMC10863884
doi:
Substances chimiques
Food Additives
0
Diglycerides
0
Fatty Acids
0
Banques de données
ClinicalTrials.gov
['NCT03335644']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1004338Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright: © 2024 Sellem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Acad Nutr Diet. 2016 Mar;116(3):427-438.e5
pubmed: 26522988
EFSA J. 2019 Jun 12;17(6):e05674
pubmed: 32626329
Front Microbiol. 2020 May 15;11:892
pubmed: 32499766
Clin Nutr. 2021 May;40(5):3608-3614
pubmed: 33388205
Cell Metab. 2020 Jan 7;31(1):62-76
pubmed: 31813823
BMJ. 2018 Feb 14;360:k322
pubmed: 29444771
EFSA J. 2017 Jul 14;15(7):e04909
pubmed: 32625570
EFSA J. 2017 Jan 20;15(1):e04646
pubmed: 32625248
JAMA Intern Med. 2020 Feb 1;180(2):283-291
pubmed: 31841598
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):1856-1868
pubmed: 32727720
EFSA J. 2020 Mar 11;18(3):e06032
pubmed: 32874250
J Gastroenterol Hepatol. 2020 Jan;35(1):110-117
pubmed: 31359491
PLoS One. 2015 Feb 13;10(2):e0118353
pubmed: 25679527
BMC Public Health. 2010 May 11;10:242
pubmed: 20459807
Food Chem Toxicol. 1983 Jun;21(3):305-11
pubmed: 6683227
BMJ. 2019 May 29;365:l1949
pubmed: 31142450
Eur J Epidemiol. 2010 May;25(5):287-96
pubmed: 20191377
EFSA J. 2017 Nov 10;15(11):e05045
pubmed: 32625340
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807577
Microbiome. 2021 Mar 22;9(1):66
pubmed: 33752754
Gastroenterology. 2022 Mar;162(3):743-756
pubmed: 34774538
JAMA Intern Med. 2019 Apr 1;179(4):490-498
pubmed: 30742202
Cancer Res. 2017 Jan 1;77(1):27-40
pubmed: 27821485
Sci Rep. 2018 Jul 3;8(1):10008
pubmed: 29968743
PLoS One. 2010 Jan 13;5(1):e8666
pubmed: 20072622
Br J Nutr. 2021 Feb 14;125(3):308-318
pubmed: 32792031
EFSA J. 2017 Apr 07;15(4):e04742
pubmed: 32625454
EClinicalMedicine. 2021 Feb 03;32:100747
pubmed: 33644723
Nutr Cancer. 2022;74(5):1701-1711
pubmed: 34353196
Exp Mol Med. 2021 Oct;53(10):1636-1646
pubmed: 34707191
Public Health Nutr. 2002 Dec;5(6B):1329-45
pubmed: 12639236
PLoS Med. 2023 Jan 17;20(1):e1004149
pubmed: 36649248
Int J Obes (Lond). 2020 Oct;44(10):2080-2091
pubmed: 32796919
EFSA J. 2018 Apr 26;16(4):e05238
pubmed: 32625873
J Crohns Colitis. 2021 Jun 22;15(6):1068-1079
pubmed: 33336247
Br J Nutr. 2016 Aug;116(3):547-58
pubmed: 27265399
Eur J Nutr. 2022 Apr;61(3):1521-1539
pubmed: 34862518
Stat Med. 2010 Apr 30;29(9):1037-57
pubmed: 20087875
Sci Transl Med. 2015 Jan 21;7(271):271ps1
pubmed: 25609166
Nutrients. 2021 Aug 13;13(8):
pubmed: 34444936
Br J Nutr. 2011 Apr;105(7):1055-64
pubmed: 21080983
Nutr Rev. 2021 May 12;79(6):726-741
pubmed: 32626902
Food Chem Toxicol. 1993 Nov;31(11):825-33
pubmed: 8258411
Int J Obes Relat Metab Disord. 2000 Sep;24(9):1119-30
pubmed: 11033980
Br J Nutr. 2015 Oct 28;114(8):1294-303
pubmed: 26299892
Int J Public Health. 2011 Aug;56(4):407-17
pubmed: 21538094
Toxicol Appl Pharmacol. 2021 Mar 1;414:115411
pubmed: 33476678
Br J Nutr. 2015 Mar 28;113(6):953-62
pubmed: 25772032
Cell Rep. 2020 Oct 6;33(1):108229
pubmed: 33027647
Nutrients. 2021 Feb 20;13(2):
pubmed: 33672720
Obes Rev. 2021 Mar;22(3):e13146
pubmed: 33167080
BMJ. 2019 May 29;365:l1451
pubmed: 31142457
Sci Rep. 2021 Oct 4;11(1):19680
pubmed: 34608173
J Med Internet Res. 2013 Aug 08;15(8):e152
pubmed: 23928492